Jolanta Dengler

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 417 citations

Life Sciences, Molecular Biology, Oncology +16

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker et al. · Journal of Clinical Oncology · 2013 · 299 citations · Full text

Medicine, Hematology, Pharmacology +13

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Dieter Hoelzer, Jan Walewski, Hartmut Döhner et al. · Blood · 2014 · 297 citations · Full text

Medicine, Oncology, Pharmacotherapy +13